Analyzing MeiraGTx (NASDAQ:MGTX) & Omeros (NASDAQ:OMER)

MeiraGTx (NASDAQ:MGTX) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings.

Earnings & Valuation

This table compares MeiraGTx and Omeros”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MeiraGTx	$81.39 million	11.42	-$114.20 million	$0.71	13.63
Omeros	$38.42 million	34.20	-$3.35 million	$1.28	14.18

Omeros has lower revenue, but higher earnings than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations for MeiraGTx and Omeros, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MeiraGTx	0	3	5	0	2.62
Omeros	0	2	3	0	2.60

MeiraGTx presently has a consensus target price of $24.00, suggesting a potential upside of 147.93%. Omeros has a consensus target price of $30.33, suggesting a potential upside of 67.13%. Given MeiraGTx’s stronger consensus rating and higher possible upside, equities analysts plainly believe MeiraGTx is more favorable than Omeros.

Profitability

This table compares MeiraGTx and Omeros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
MeiraGTx	19.87%	283.85%	29.39%
Omeros	N/A	-164.92%	69.41%

Institutional & Insider Ownership

67.5% of MeiraGTx shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 7.4% of MeiraGTx shares are held by insiders. Comparatively, 10.5% of Omeros shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

MeiraGTx has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Omeros has a beta of 2.96, indicating that its stock price is 196% more volatile than the S&P 500.

About MeiraGTx

MeiraGTx Holdings plc is a biotechnology company developing gene therapies for serious diseases with limited treatment options. Its research focuses on using adeno-associated virus (AAV) vectors to deliver genetic material to target cells, including in programs for inherited retinal diseases, neurological conditions and salivary gland dysfunction. The company also develops manufacturing capabilities and technologies intended to support the production of gene therapies. MeiraGTx was founded in 2015 and has operations in the United States and the United Kingdom.

About Omeros

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for disorders involving the complement, immune and coagulation systems. The company has also developed a pipeline of investigational therapies aimed at treating serious diseases involving complement activation and immune-system dysfunction. The company is headquartered in Seattle, Washington, and was founded in 1994. Its leading investigational programs have included narsoplimab, which targets the lectin pathway of the complement system, and OMS906, an antibody designed to inhibit MASP-3 and regulate the alternative pathway.